121 related articles for article (PubMed ID: 10576812)
1. [Under what conditions should we propose a prophylactic mastectomy for a woman at risk?].
Gauthier-Villars M; Blandy C; Stoppa-Lyonnet D
Bull Cancer; 1999 Sep; 86(9):754-9. PubMed ID: 10576812
[No Abstract] [Full Text] [Related]
2. Hereditary breast cancer.
Robson ME; Boyd J; Borgen PI; Cody HS
Curr Probl Surg; 2001 Jun; 38(6):387-480. PubMed ID: 11375625
[No Abstract] [Full Text] [Related]
3. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
4. Complex decision-making for BRCA1/2 carriers.
Matloff ET
Cancer J Sci Am; 1999; 5(5):266-8. PubMed ID: 10526666
[No Abstract] [Full Text] [Related]
5. Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations--facts and controversy.
Eisen A; Weber BL
N Engl J Med; 2001 Jul; 345(3):207-8. PubMed ID: 11463017
[No Abstract] [Full Text] [Related]
6. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition].
Ruiz-Flores P; Calderón-Garcidueñas AL; Barrera-Saldaña HA
Rev Invest Clin; 2001; 53(1):46-64. PubMed ID: 11332051
[TBL] [Abstract][Full Text] [Related]
7. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
9. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
10. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
11. Are local recurrences after breast conserving therapy more frequent in patients with BRCA1/BRCA2 mutations?
Kurtz JM
Strahlenther Onkol; 2000 Sep; 176(9):433-4. PubMed ID: 11050918
[No Abstract] [Full Text] [Related]
12. [Generic screening for breast cancer].
Ponti A; Giordano L
Epidemiol Prev; 1999; 23(4):369-71. PubMed ID: 10730478
[TBL] [Abstract][Full Text] [Related]
13. Sex steroid hormones and genetic susceptibility to breast and prostate cancer.
Feigelson HS; Ross RK; Yu MC; Coetzee GA; Reichardt JK; Henderson BE
Drug Metab Rev; 1998 May; 30(2):421-34. PubMed ID: 9606611
[No Abstract] [Full Text] [Related]
14. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
15. Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
Kiechle M; Gross E; Schwarz-Boeger U; Pfisterer J; Jonat W; Gerber WD; Albacht B; Fischer B; Schlegelberger B; Arnold N
Hum Mutat; 2000 Dec; 16(6):529-30. PubMed ID: 11102986
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T
Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836
[TBL] [Abstract][Full Text] [Related]
17. BRCA: the breast, ovarian, and other cancer genes.
Boyd J
Gynecol Oncol; 2001 Mar; 80(3):337-40. PubMed ID: 11263927
[No Abstract] [Full Text] [Related]
18. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
19. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
[TBL] [Abstract][Full Text] [Related]
20. [Pregnancy and risk of early breast cancer in patients sith BRCA1 and BRCA2 mutations].
Ost E; Illiger HJ
Strahlenther Onkol; 2000 Jul; 176(7):335-6. PubMed ID: 10963002
[No Abstract] [Full Text] [Related]
[Next] [New Search]
